Literature DB >> 15737885

The penetrance of hereditary hemochromatosis.

Jill Waalen1, Børge G Nordestgaard, Ernest Beutler.   

Abstract

Since its original description as a rare disease of iron overload resulting in liver disease, diabetes mellitus, and bronzing of the skin ('bronze diabetes'), hereditary hemochromatosis has undergone several redefinitions leading to widely varying estimates of its prevalence. Over the last decade, the finding of a relatively high prevalence of the C282Y polymorphism of the HFE gene associated with hemochromatosis in Northern European populations suggested that the disease may be much more common than previously thought. However, several large population-based studies have now shown that the penetrance of the C282Y/C282Y genotype is very low, indicating that C282Y homozygosity is a necessary but not sufficient factor in causation of the disease. Studies are now focusing on other genetic and environmental factors, including alcohol, that may contribute to differential expression of C282Y homozygosity.

Entities:  

Mesh:

Year:  2005        PMID: 15737885     DOI: 10.1016/j.beha.2004.08.023

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  20 in total

1.  Epistasis in iron metabolism: complex interactions between Cp, Mon1a, and Slc40a1 loci and tissue iron in mice.

Authors:  Constance Delaby; Vincent Oustric; Caroline Schmitt; Francoise Muzeau; Anne-Marie Robreau; Philippe Letteron; Eric Couchi; Angel Yu; Saïd Lyoumi; Jean-Charles Deybach; Herve Puy; Zoubida Karim; Carole Beaumont; Bernard Grandchamp; Peter Demant; Laurent Gouya
Journal:  Mamm Genome       Date:  2013-12       Impact factor: 2.957

2.  A patient with a rare cause of elevated troponin I.

Authors:  Antonios Kilias; Karin Klingel; Meinrad Gawaz; Ulrich Kramer; Peter Seizer
Journal:  Clin Res Cardiol       Date:  2015-04-28       Impact factor: 5.460

3.  Insufficient referral for genetic counseling in the management of hereditary haemochromatosis in portugal: a study of perceptions of health professionals requesting HFE genotyping.

Authors:  Bruna Leandro; Milena Paneque; Jorge Sequeiros; Graça Porto
Journal:  J Genet Couns       Date:  2014-01-08       Impact factor: 2.537

4.  Acquired hemochromatosis with pronounced pigment deposition of the upper eyelids.

Authors:  Anna H Chacon; Brian Morrison; Shasa Hu
Journal:  J Clin Aesthet Dermatol       Date:  2013-10

5.  [Osteoarthritis in hereditary metabolic diseases].

Authors:  J Zwerina; T Dallos
Journal:  Orthopade       Date:  2010-06       Impact factor: 1.087

Review 6.  Factors influencing disease phenotype and penetrance in HFE haemochromatosis.

Authors:  J Rochette; G Le Gac; K Lassoued; C Férec; K J H Robson
Journal:  Hum Genet       Date:  2010-07-06       Impact factor: 4.132

Review 7.  [Osteoarthritis in hereditary metabolic diseases].

Authors:  J Zwerina; T Dallos
Journal:  Z Rheumatol       Date:  2010-05       Impact factor: 1.372

8.  Heme carrier protein 1 (HCP1) genetic variants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study participants.

Authors:  XinJing Wang; Catherine Leiendecker-Foster; Ronald T Acton; James C Barton; Christine E McLaren; Gordon D McLaren; Victor R Gordeuk; John H Eckfeldt
Journal:  Blood Cells Mol Dis       Date:  2009-01-26       Impact factor: 3.039

9.  Relationship between gene expression of duodenal iron transporters and iron stores in hemochromatosis subjects.

Authors:  James E Nelson; Virginia R Mugford; Ellen Kilcourse; Richard S Wang; Kris V Kowdley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-05       Impact factor: 4.052

10.  HFE-Related Hemochromatosis: The Haptoglobin 2-2 Type Has a Significant but Limited Influence on Phenotypic Expression of the Predominant p.C282Y Homozygous Genotype.

Authors:  Gérald Le Gac; Chandran Ka; Isabelle Gourlaouen; Laurence Bryckaert; Anne-Yvonne Mercier; Brigitte Chanu; Virginie Scotet; Claude Férec
Journal:  Adv Hematol       Date:  2009-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.